Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $650.00 Price Target at Citigroup

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) had its price objective reduced by research analysts at Citigroup from $700.00 to $650.00 in a research report issued on Monday,Benzinga reports. The brokerage presently has a "buy" rating on the biopharmaceutical company's stock. Citigroup's price objective suggests a potential upside of 33.23% from the stock's previous close.

A number of other equities research analysts have also issued reports on the stock. Canaccord Genuity Group raised shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, April 22nd. BMO Capital Markets dropped their target price on shares of Regeneron Pharmaceuticals from $800.00 to $600.00 and set an "outperform" rating on the stock in a report on Monday. Wall Street Zen lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 1st. The Goldman Sachs Group decreased their target price on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating on the stock in a research report on Wednesday, April 30th. Finally, Bernstein Bank decreased their target price on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. One analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $847.40.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN traded down $2.95 on Monday, hitting $487.86. The stock had a trading volume of 2,139,444 shares, compared to its average volume of 844,356. The company's 50-day moving average is $581.26 and its two-hundred day moving average is $663.80. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The stock has a market cap of $52.67 billion, a price-to-earnings ratio of 12.74, a P/E/G ratio of 2.34 and a beta of 0.43. Regeneron Pharmaceuticals has a one year low of $481.58 and a one year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The business had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company's quarterly revenue was down 3.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $9.55 earnings per share. On average, analysts expect that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of REGN. Pinney & Scofield Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth approximately $25,000. E Fund Management Hong Kong Co. Ltd. increased its stake in Regeneron Pharmaceuticals by 344.4% in the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 31 shares in the last quarter. Activest Wealth Management increased its stake in Regeneron Pharmaceuticals by 110.5% in the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 21 shares in the last quarter. Costello Asset Management INC bought a new stake in Regeneron Pharmaceuticals in the first quarter valued at approximately $27,000. Finally, Saudi Central Bank bought a new stake in Regeneron Pharmaceuticals in the first quarter valued at approximately $27,000. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.